Seelos therapeutics receives a notice of allowance in japan for sls-005 (trehalose)

New york, jan. 22, 2021 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received a notice of allowance from the...
SEEL Ratings Summary
SEEL Quant Ranking